52F6F0A9-8D2D-49BC-9B49-E20E5E53561C
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 15.768725361366622
- age_years
- 62
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.634
- ANGIOGENESIS+0.600
- E2F_TARGETS+0.571
- MYC_TARGETS_V2+0.549
- OXIDATIVE_PHOSPHORYLATION+0.544
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.525
- G2M_CHECKPOINT+0.524
- DNA_REPAIR+0.504
- MTORC1_SIGNALING+0.462
- PROTEIN_SECRETION+0.425
Top 10 suppressed
- KRAS_SIGNALING_DN-0.441
- PANCREAS_BETA_CELLS-0.227
- SPERMATOGENESIS-0.148
- MYOGENESIS-0.129
- HEDGEHOG_SIGNALING-0.105
- APICAL_SURFACE-0.081
- HEME_METABOLISM+0.054
- INFLAMMATORY_RESPONSE+0.056
- ESTROGEN_RESPONSE_EARLY+0.058
- BILE_ACID_METABOLISM+0.067
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 94640BD8-E1D9-482D-A597-4790F6EEA6B7 | — | — | 0.975 |
| 2 | 769432C5-4BFD-4689-8F43-467010292448 | — | — | 0.962 |
| 3 | 55E3F1FB-D55D-42F8-A9E1-7828F7BFF595 | — | — | 0.961 |
| 4 | 46061E4B-5256-42AD-BA9A-FBCEBE92B09A | — | — | 0.959 |
| 5 | EBE58DF8-7300-4D3E-9672-A4E7ADF46113 | — | — | 0.956 |
| 6 | C5C8713B-05C1-4C5C-8685-2A546B99BA50 | — | — | 0.956 |
| 7 | 633064DB-D3ED-4B5F-B48F-6924AD719647 | — | — | 0.955 |
| 8 | 66FF1C46-83F0-4EEC-9871-448C8C7EA3AE | — | — | 0.955 |
| 9 | 0E66EFB0-712B-4A52-8F75-A37F030CABEF | — | — | 0.955 |
| 10 | E317AD4C-E877-499A-B108-2F39A40D1682 | — | — | 0.952 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 44 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.634 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.600 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.571 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.549 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.544 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.525 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.524 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.504 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.462 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.425 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.411 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.402 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.382 | Inavolisib | — uncovered |
| APOPTOSIS | 0.376 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.374 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.366 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.364 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.340 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.336 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.334 | Inavolisib | — uncovered |